Mendelian randomization applied to pharmaceutical use: the case of metformin and lung cancer

Abstract excerpt

Zhou et al. recently reported findings from a Mendelian randomization analysis aiming to examine the causal relationship between metformin use and lung cancer risk.1 This is a topical question because of previously reported associations between use of metformin, a commonly prescribed drug for the treatment of type 2 diabetes, and lower cancer risk across several anatomical sites, including lung cancer.2,3 In lieu...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer-related Molecular Pathways
• Share to Metabolism, Diabetes, and Cancer
• Share to PI3K/AKT/mTOR signaling in cancer